| Document |
Document Title |
|
WO/2018/120920A1 |
Disclosed is a cisatracurium besilate lyophilized powder-injection preparation for intravenous administration, which is made of the following components in parts by weight: 1-5 parts of cisatracurium besilate, 10-40 parts of dimyristoylp...
|
|
WO/2018/121427A1 |
An application of a combination of polyethylene glycol and a local anesthetic in non-narcotic analgesia. The local anesthetic is prepared into a prodrug or a sustained-release preparation; in the prodrug, a high molecular polymer, such a...
|
|
WO/2018/108319A1 |
The present invention relates to tetrahydropyran and tetrahydrothiopyran amide derivatives having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opioid receptor, to processes of preparation of such compoun...
|
|
WO/2018/103119A1 |
The present invention provides a hydrobromate of methyl 3-[(4S)-8-bromo-1-methyl-6-(2-pyridyl)-4H-imidazole[1,2-a][1
,4]benzodiazepine-4-yl]propionate and related crystal forms and preparation method and use thereof. The hydrobromate has...
|
|
WO/2018/094470A1 |
The present invention relates generally to methods and compositions for reducing the side effects of neuroexcitation associated with general anaesthetic agents by using cannabinoid- 1 receptor antagonists (CB IR) or inverse agonists. The...
|
|
WO/2018/091687A1 |
The disclosure provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I): (I) or an isotope labelled analog thereof, or a pharmaceutically acceptable salt thereof, wherein: each of R...
|
|
WO/2018/052039A1 |
[Problem] To provide a nonaqueous patch which shows a skin permeation rate of a drug within an appropriate range when applied to the skin, enables long-lasting and continuous drug permeation without causing the depletion of the drug at t...
|
|
WO/2018/048460A1 |
Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Al...
|
|
WO/2018/039759A1 |
The present invention describes a healing, anaesthetic and anti-inflammatory film comprising a natural polymer and medicinal plants native to the Brazilian flora, more precisely Spilanthes acmella and Achyrocline satureioides, commonly c...
|
|
WO/2018/014770A1 |
The present invention relates to a phenol-containing derivative, an etomidate pharmaceutical composition, a preparation method thereof, and application of same in the field of central nervous system treatment. A phenol derivative is a co...
|
|
WO/2017/211937A1 |
The present invention relates to FLT3 receptor inhibitor for use in the treatment of neuropathic pain and chronic pain comprising a neuropathic component, wherein the daily dosage range per human adult per day of said FLT3 receptor inhib...
|
|
WO/2017/210390A1 |
The present invention relates to intranasally administered pharmaceutical compositions administered for use in anesthesia. Such pharmaceutical compositions comprise benzyl alcohol. The invention also relates to methods for anesthetizing ...
|
|
WO/2017/210498A1 |
Provided herein are compositions and methods for managing and minimizing chronic pain. In particular, provided herein are systems and methods for managing and minimizing chronic pain with light therapy.
|
|
WO/2017/197970A1 |
A pharmaceutical composition containing bupivacaine comprises: bupivacaine or a pharmaceutically acceptable salt thereof serving as an active ingredient; and one or more pharmaceutically acceptable carrier materials. Particularly, the ph...
|
|
WO/2017/201297A1 |
Disclosed are compositions, methods of treatment using the compositions and methods of preparing the compositions for the treatment of eczema. The compositions may include propionic acid and/or non-steroidal esters of propionic acid. The...
|
|
WO/2017/194835A1 |
The present invention relates to compositions for use in sedation and/or anesthesia, where the composition comprises MK-467 and a psychoactive drug selected from opioids, benzodiazepines, NMDA receptor antagonists and combinations thereo...
|
|
WO/2017/193066A1 |
A composition to induce analgesia includes a plurality of particles, each particle of the plurality having 40-60 wt% amino amide anesthetic or a pharmaceutically acceptable salt, hydrate, or solvate thereof and 60-40 wt% PLGA polymer inc...
|
|
WO/2017/178663A1 |
The present invention relates to Orally Inhaled and Nasal Drug Product (OINDP) comprising a benzodiazepine, in particular remimazolam.
|
|
WO/2017/165747A1 |
Compositions and methods for treating, inhibiting, and/or preventing pain, particularly neuropathic pain, are provided.
|
|
WO/2017/149179A1 |
The invention relates to an anaesthetic solution comprising a natural anaesthetising agent (clove essential oil, isoeugenol and/or eugenol) nanoencapsulated in food-grade β-cyclodextrines, with a moisture content no greater than 14%, fo...
|
|
WO/2017/146053A1 |
Provided are: pharmaceutical composition particles and an orally disintegrating tablet including the same which are capable of achieving both the masking of unpalatable taste and an improvement in elution properties; and a method for pro...
|
|
WO/2017/136935A1 |
A biocompatible, degradable dermal filler system is composed of unmodified macroporous chitosan microbeads dispersed uniformly in a continuous phase composed of cross-linked hyaluronic acid gel particles and unmodified hyaluronic acid.
|
|
WO/2017/139487A1 |
Methods, agents, and devices to treat medical conditions through local chemical neuromodulation of the autonomic nervous system are described. Drug formulations may be injected at or near ganglia, nerve plexi, ganglionated plexi, and ner...
|
|
WO/2017/133517A1 |
Disclosed are a phosphamide derivative, a method for manufacturing the same, and uses thereof Particularly disclosed are a compound shown by general formula (I) as well as a pharmaceutically acceptable salt or stereisomer (I) thereof, wh...
|
|
WO/2016/105482A9 |
The present invention relates to tetracaine based anesthetic formulations and methods of use thereof. The present invention also relates to tetracaine based dental anesthetic formulations and methods for anesthetizing the upper back mola...
|
|
WO/2017/113011A1 |
A transdermal drug delivery device comprises: a reservoir for holding a drug; and at least one microneedle in fluid communication with the reservoir through which the drug can be delivered transdermally, wherein the transdermal drug deli...
|
|
WO/2017/105881A1 |
The invention provides novel chemical compounds useful for treating pain or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof.
|
|
WO/2017/101808A1 |
The present invention relates to a benzodiazepine derivative having formula (I) and acting as a short-acting anesthetic, a pharmaceutical composition including the benzodiazepine derivative, a drug kit including the benzodiazepine deriva...
|
|
WO/2017/096469A1 |
An hydrogel comprising a colloidal suspension of ΜI χΜII yΡZ two-dimensional nanocrystals In water, wherein MI is Na+ and/or Li+, MII is Mg2+ or a mixture of Mg2+ with one or more Ni2+, Zn2+, Cu2+, Fe2+ and/or Mn2+, P is a mixture of...
|
|
WO/2017/087691A1 |
Methods for prophylactically treating a stress-induced affective disorder or stress- induced psychopathology in a subject are provided. Also provided are methods for inducing and/or enhancing stress resilience in a subject. In certain em...
|
|
WO/2017/075232A1 |
Described herein are sustained release formulations of polymer-coated local anesthetic agents, and methods for using the same to relieve or manage pain, including postsurgical pain.
|
|
WO/2017/069672A1 |
A pharmaceutical composition for treating infertility in a female subject substantially consists of local anesthetic of amide type such as lidocaine, human albumin, viscosity controlling agent selected from recombinant hyaluronic acid an...
|
|
WO/2017/066787A1 |
Compounds are provided according to Formula (I), and hydrates thereof, and compositions thereof; and methods of using and making the same. Compounds of the present invention are contemplated useful for suppressing pain during cosmetic, m...
|
|
WO/2017/059827A1 |
Disclosed are an etomidate derivative of formula 1 or a pharmaceutically acceptable salt, a polymorph or a solvate thereof, a pharmaceutical composition and a kit comprising the etomidate derivative, and an intermediate, a preparation me...
|
|
WO/2017/036408A1 |
Provided are a long-effective amide local anesthetic: S-(-)-1-propyl-2',6'-aminoxyleneformylpiperidine crystal, a sustained release preparation thereof, and their preparation method. Compared with an existing hydrochloride preparation, t...
|
|
WO/2017/034041A1 |
The present invention relates to non-aqueous patches containing lidocaine.
|
|
WO/2017/027529A1 |
Amblyopia is a prevalent form of visual impairment that generally arises during infancy and early childhood when inputs to the visual cortex form the two eyes are poorly balanced. Disclosed herein are methods involving retinal inactivati...
|
|
WO/2017/026386A1 |
The present invention addresses the problem of providing a patch that has a practical adhesiveness and cohesive force for medicinal use and provides an immediate anesthetic effect. Provided is a patch formed of an adhesive layer, said ad...
|
|
WO/2017/014664A1 |
The invention relates to the field of manufacturing articles from sanitary and domestic paper, and more particularly relates to the manufacture of sanitary wipes, toilet paper and tampons. The aim of the invention is to improve the prope...
|
|
WO/2016/206549A1 |
A conjugate represented by general formula (I), wherein R0 is a C1-6 alkyl, and B is an anesthetic, and A is a linking group, and a quaternary ammonium salt is formed at a linking position between B and R0. The conjugate has a prolonged ...
|
|
WO/2016/205533A1 |
Pharmaceutical compositions and methods are described, the compositions comprising a benzodiazepine-based compound, a NMDA antagonist, a beta-blocker and antiemetic. Methods for fabricating the compositions and using them for anesthesiol...
|
|
WO/2016/165101A1 |
The present invention provides a peptide with sequence of DEAQETAVSSHEQD, a fragment of rabbit-α1 antiproteinase F, and its derivatives DEAQETAVSSHEQ and QETACSSHEQD, which significantly inhibit serum-borne HCV replication in hADSC and ...
|
|
WO/2016/152186A1 |
The gel local anesthetic agent according to the present invention is a local anesthetic agent comprising a local anesthetic having a tertiary amine and glycyrrhizic acid, wherein the local anesthetic and glycyrrhizic acid set to a gel to...
|
|
WO/2016/140629A1 |
The present invention relates to the topical composition comprising Calendula officinalis, Hypericum perforatum and a local anesthetic.
|
|
WO/2016/135308A1 |
Specific mixtures comprising one or more (cannabinoid) compounds of the formula (A) and/or one or more of the salts thereof are described, as are processes for the preparation thereof. Also described are a compound of the formula (A), a ...
|
|
WO/2016/137411A1 |
The present invention relates to the preparation of stable topical pharmaceutical composition comprising ibuprofen and lidocaine. Preferably, the composition is topical spray.
|
|
WO/2016/137352A1 |
A pharmaceutical composition having an analgesic, anaesthetic and antiseptic action, a method for producing the pharmaceutical composition and a method for the treatment of otitis and other ear injuries. The group of inventions relate...
|
|
WO/2016/126217A1 |
The present invention relates to the preparation of stable pharmaceutical compositions comprising benzydamine hydrochloride as an anti-inflammatory agent, cetylpyridinium as an quaternary ammonium compound of antiseptics, lidocaine hydro...
|
|
WO/2016/124162A1 |
A propanidid pharmaceutical composition, comprising propanidid, oil for injection, phospholipid, and water for injection, the parts by weight of propanidid being 1 to 10, the parts by weight of oil for injection being 10 to 60, the parts...
|
|
WO/2016/123270A1 |
This invention provides compositions, kits containing compositions, and methods for their use in treating subjects with pain. Instant compositions comprise two or more long acting aminoamide local anesthetics, at least one NSAID, at leas...
|
